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Aims: Type 2 diabetes, hyperinsulinemia, and insulin resistance are associated with cognitive impairment.
Experimental studies indicate that insulin signaling in the brain is related to cognitive performance. Here we
evaluated whether insulin-related variables contribute to the variance in cognitive performance among
individuals with type 2 diabetes.
Methods: A total of 806 individuals with type 2 diabetes (mean age 62 ± 8 years, HbA1c 6.9 ± 1.1%)
completed a neuropsychological test battery. Insulin-related variables evaluated were: fasting plasma insulin,
C-peptide, and the Homeostasis Model Assessment (HOMA2-IR; in individuals without insulin treatment;
n = 641). The unadjusted coefficient of determination (R2), obtained from multiple linear regression
analyses, was used to estimate the proportion of variance in cognition explained by insulin-related variables.
Results: Sex, age, and educational level together explained 18.0% (R2) of the variance in memory function,
26.5% in information processing speed, and 22.8% in executive function and attention. Fasting insulin,
C-peptide, or HOMA2-IR did not increase the explained variance (maximum ΔR2 0.3%, P ≥ 0.14). Similar
results were obtained when insulin-related variables were added to models that additionally included
glycemic control, cardiovascular risk factors, and depression.
Conclusions: Our results show that measures of peripheral insulin resistance are unrelated to cognitive
performance among individuals with adequately controlled type 2 diabetes.© 2017 Elsevier Inc. All rights reserved.1. Introduction
Type 2 diabetes is known to be associated with cognitive
dysfunction. The severity of diabetes-associated cognitive changes
varies, ranging from subtle cognitive decrements to mild cognitive
impairment and dementia.1 Yet it is unclear why individuals with
type 2 diabetes develop these cognitive changes. Given the ongoing
diabetes epidemic and the increasing life-expectancy of individuals
with type 2 diabetes,2 there is an urgent need to identify factors thatearch support from Boehringer
received speaker's fees from Eli
eclare.
ical Center +, Department of
Z, Maastricht, the Netherlands.
Geijselaers).contribute to the severity and progression of cognitive problems
among individuals with type 2 diabetes.
We recently conducted a systematic review of the literature to
examine whether abnormalities in glucose regulation, the hallmark of
diabetes, are related to cognitive performance among individuals with
type 2 diabetes.3 Based on the findings of 86 papers, we concluded
that measures of glycemia, particularly glycated hemoglobin (HbA1c)
and glucose variability, are negatively, but weakly, associated with
cognitive performance. We also noted that, compared to glycemia, far
less is currently known about the association of hyperinsulinemia and
insulin resistance with cognitive performance among individuals with
type 2 diabetes.3 This topic is clearly worthy of further study, not only
because these insulin-related measures have been found to be
inversely associated with cognitive performance in individuals
without diabetes (e.g.4–6), but especially because experimental
studies have linked insulin signaling to normal brain functioning, as
well as to brain disease.7
825S.L.C. Geijselaers et al. / Journal of Diabetes and Its Complications 31 (2017) 824–830The aim of the present study was to assess whether insulin-related
variables (i.e. fasting insulin, C-peptide, and the Homeostasis Model
Assessment of Insulin Resistance (HOMA2-IR)) contribute to the variance
in cognitive performance among individuals with type 2 diabetes.
2. Material and methods
2.1. Study population
We used data from The Maastricht Study, an observational
prospective population-based cohort study enriched with individuals
with type 2 diabetes. The rationale and methodology have been
described previously.8 In brief, the study focuses on the etiology,
pathophysiology, complications, and comorbidities of type 2 diabetes
and is characterized by an extensive phenotyping approach. Eligible
for participation were all individuals aged between 40 and 75 years
living in the southern part of the Netherlands. Participants were
recruited through mass media campaigns and from the municipal
registries and the regional Diabetes Patient Registry via mailings.
For the present study, cross-sectional data from the first 975
participants with type 2 diabetes were used, who completed the
baseline survey between November 2010 and September 2013.
Diabetes status was determined by a 75-g oral glucose tolerance test
and defined according to the 2006WorldHealthOrganization9 diagnostic
criteria, as described in more detail before.8 Participants were also
considered to have type 2 diabetes if they used glucose-lowering
medication without a prior diagnosis of type 1 diabetes.
The Maastricht Study was approved by the institutional medical
ethical committee (NL31329.068.10) and the Minister of Health,
Welfare and Sports of the Netherlands, on the basis of the Health
Council's opinion (Permit 131088-105234-PG). All participants gave
written informed consent.
2.2. Insulin-related variables
The following insulin-related variables were considered in the
present study: fasting insulin, C-peptide, and HOMA2-IR. Both insulin
and C-peptide were included as they provide similar but comple-
mentary information. Specifically, while insulin and C-peptide are
secreted in equimolar amounts by the pancreatic β-cells, C-peptide is
not extracted from the circulation by the liver, and hence its half-life is
longer than that of insulin,10 which might make it a more stable and
reliable reflector of insulin secretion. In addition, recent research has
shown that C-peptide interacts with insulin and may prevent
neuronal loss and cognitive deficits in experimental type 1 diabetes.11
All insulin-related variables were based on venous blood samples,
which were collected after an overnight fast. Serum and plasma were
separated after centrifugation (3000 ×g for 15 min at 4 °C) and were
stored at −80 °C until the assays were performed.
Insulin and C-peptide were quantified on a Meso Scale custom
duplex assay (Meso Scale Discovery, Gaithersburg, MD, USA). In short,
96-well plates, with capture antibodies against insulin and C-peptide
patterned on distinct spots in the same well, were supplied by the
manufacturer. Samples (10 μL/well), detection antibodies, and read
buffer for electrochemiluminescence were applied according to
manufacturer's instruction, and plates were read using a SECTOR®
2400 Imager. Detection ranges of the assay were 35–25,000 pg/mL for
insulin and 70–50,000 pg/mL for C-peptide. Interassay coefficients of
variation for insulin and C-peptide were 10.1% and 8.2%, respectively.
Insulin and C-peptide were converted from pg/mL to pmol/L using a
molar mass of 5808 g for insulin and 3010 g for C-peptide.
Insulin resistance was estimated from fasting insulin and glucose
by the Homeostasis Model Assessment of Insulin Resistance
(HOMA2-IR) and calculated by using the HOMA2 calculator (version
2.2.3 for Windows; available from https://www.dtu.ox.ac.uk/
homacalculator). The fasting plasma glucose concentrations requiredto calculate HOMA2-IR were measured in venous blood samples with
the enzymatic hexokinase method using two automatic analyzers
(i.e. the Beckman Synchron LX20 [Beckman Coulter Inc., USA] for
samples obtained between November 2010 and April 2012, and the
Roche Cobas 6000 [Roche Diagnostics, Mannheim, Germany] for
samples obtained thereafter). Because the HOMA2-IR has not been
validated for individuals using exogenous insulin,12 calculations were
limited to those not treated with insulin.
2.3. Cognitive performance
A concise (30 min) neuropsychological test battery was applied to
assess cognitive performance.8 Test scores were standardized and
divided into three cognitive domains (i.e. memory function, executive
function and attention, and information processing speed), as detailed
in the Supplementary Material. In short, memory function was
evaluated using the Verbal Learning Test by calculating the mean of
total immediate and delayed recall scores. The composite score for
information processing speed was derived from the Stroop Color
Word Test Part I and II, the Concept Shifting Test Part A and B, and the
Letter–Digit Substitution Test. Executive function and attention was
assessed by the Stroop Color Word Test Part III and the Concept
Shifting Test Part C. Raw test scores were standardized using themean
and the standard deviation of the subpopulation with type 2 diabetes
rather than thewholeMaastricht Study population.Where appropriate,
individual test scores were inverted so that higher scores indicated
better cognitive performance.
2.4. Covariates
Fasting serum total cholesterol and high-density lipoprotein (HDL)
cholesterol were measured with standard enzymatic methods on the
same auto-analyzers as used to measure glucose. HbA1c was
measured with ion-exchange high performance liquid chromatogra-
phy. Questionnaires were used to gather information on, among
others, diabetes duration, smoking behavior (never/former/current),
and history of cardiovascular disease (CVD), as described in detail
before.8 Personal interviews were conducted to evaluate medication
use8 and determine educational level, which was categorized as low,
intermediate, or high.13 Suspected presence of a depression was
assessed with the Mini International Neuropsychiatric Interview
(MINI).8 Waist circumference was measured in duplicate midway
between the lower rib margin and the iliac crest at the end of
expiration and recorded to the nearest 0.5 cm. Systolic and diastolic
blood pressures were calculated as the average of at least three
consecutive blood pressure readings (Omron 705IT, Omron Corpora-
tion, Kyoto, Japan) performed after a minimum of 10 min seated rest.
Data on 24-h ambulatory blood pressure monitoring (WatchBP03,
Microlife AG,Widnau, Switzerland)8 were only available in a subset of
participants (n = 712).
2.5. Statistical analyses
All statistical analyses were performed with use of SPSS version
20.0 for Windows and version 23.0 for Mac (IBM SPSS, IBM Corp,
Armonk, NY, USA). Fasting insulin concentrations and HOMA2-IR
values were transformed with the natural logarithm prior to analyses
because of non-normal distribution. A two-sided p-value b0.05 was
considered statistically significant, except for interaction analyses,
where the significance level was set at 0.10.
Multiple linear regression analyses were performed to test
whether insulin-related variables contributed to the variance in
cognitive performance among individuals with type 2 diabetes. To this
end, the unadjusted coefficient of determination, referred to as
R-squared (R2) and reflecting explained variance, was used as effect
estimate. More specifically, fasting insulin, C-peptide, and HOMA-IR
Table 1
Characteristics of the study population (n = 806).
Age (years) 62 ± 8
Sex (male/female) 542/264
Educational level, low/middle/high 215/357/234 (26.7%/44.3%/29.0%)
Diabetes duration (years)a 6 [3–12]
HbA1c (%) 6.9 ± 1.1
HbA1c (mmol/mol) 52 ± 12
Fasting glucose (mmol/l) 7.9 ± 2.0
Fasting insulin (pmol/l) 85 [53–134]
C-peptide (nmol/l) 0.85 ± 0.43
Glucose-lowering medication, any typeb 628 (91.4%)
Insulin 165 (24.0%)
Oral glucose-lowering medication 591(86.0%)
Alpha-glucosidase inhibitors 0 (0%)
Biguanides 562 (81.8%)
DPP-4 inhibitors 51 (7.4%)
Sulfonylurea derivatives 168 (24.5%)
Thiazolidinediones 8 (1.2%)
Glucagon-like peptide-1 analogues 7 (1.0%)
Waist circumference (cm) 105 ± 13
Total cholesterol (mmol/L) 4.5 ± 1.0
HDL-cholesterol (mmol/L) 1.3 ± 0.4
Triglycerides (mmol/L) 1.5 [1.1–2.1]
Lipid-modifying medication 594 (73.7%)
Systolic blood pressure (mmHg)c 142 ± 18
Diastolic blood pressure (mmHg)c 77 ± 9
Hypertensiond 669 (83.0%)
Antihypertensive medication 577 (71.6%)
Smoking behavior, never/former/current 223/455/128 (27.7%/56.5%/15.9%)
Prior cardiovascular disease 218 (27.0%)
Current depression 76 (9.4%)
Data are presented as mean ± SD, median [IQR], or n (%).
Abbreviation: DPP-4 = dipeptidyl peptidase-4.
a Data available for n = 570.
b Data available for individuals with known type 2 diabetes (n = 687).
c Obtained from office blood pressure measurements.
d Hypertension was defined as a systolic blood pressure ≥ 140 mmHg (based on
office blood pressure measurements), a diastolic blood pressure ≥ 90 mmHg, and/or
current use of antihypertensive medication.
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regression models: model 1 demographic factors (i.e. age, sex, and
educational level);model 2 demographic factors and glycemic control
(i.e. fasting glucose and HbA1c); and model 3 demographic factors,
glycemic control, cardiovascular risk factors (i.e. waist circumference,
total/HDL-cholesterol ratio, use of lipid-modifying medication,
systolic and diastolic blood pressure, use of antihypertensive
medication, and smoking behavior), and the presence of a depression.
The incremental change in explained variance was assessed
and statistically tested by the corresponding F-tests. In addition to
changes in R2, we also report standardized regression coefficients
that reflect the associations between insulin-related variables and
cognitive performance.
We used multiplicative interaction terms to examine whether any
association between insulin-related variables and cognitive perfor-
mance differed between individuals previously diagnosed with
diabetes and those newly diagnosed at study entry, by gender, or by
age. Non-linearity of the associations between fasting insulin or
C-peptide and cognitive performance was explored by entering linear
and quadratic terms of the mean-centered variables to the regression
model, as at least fasting insulin concentrations have been shown to
be quadratically associated with dementia risk in older individuals.14
As a sensitivity analysis, we re-examined the association between
fasting insulin and cognitive performance after the exclusion of
individuals treated with insulin and after additional exclusion of
individuals treated with oral glucose-lowering medication that
potentially enhances insulin secretion (i.e. dipeptidyl peptidase-4
inhibitors, sulfonylurea derivatives, and glucagon-like peptide-1
analogues). We also checked whether outliers influenced the results
by excluding individuals with fasting insulin or C-peptide concentra-
tions that were three standard deviations away from the sample
mean. Finally, to test the robustness of our findings, analyses were
rerun with adjustment for 24-h ambulatory blood pressure instead of
office blood pressure (n = 712), as well as with additional adjust-
ment for diabetes duration (n = 570) or history of CVD.
3. Results
Of the first 975 individuals with type 2 diabetes who completed
the baseline survey of The Maastricht Study, 114 (11.7%) had no, or
incomplete, data onmeasures of cognitive performance, and 22 (2.3%)
had missing data on fasting insulin or C-peptide concentrations. An
additional 38 (3.9%) individuals were excluded from the present
analyses because of missing data on covariates, resulting in a final
study population of 806 individuals. Differences in demographic,
clinical, and diabetes-related characteristics between individuals
with complete and incomplete data are depicted in Table A1
(Supplementary Material). Notably, those excluded were generally
older and less well educated.
Characteristics of the final study population are presented in
Table 1. The mean age was 62 ± 8 years, 67.2% of the individuals
were men, and 119 (14.8%) were newly diagnosed with diabetes at
study entry. Individuals with known type 2 diabetes had a median
disease duration of 6 years and their overall glycemic control was
good with a mean HbA1c of 7.0% (53 mmol/mol). Mean HbA1c
concentrations were 6.2% (44 mmol/mol) in individuals with newly
diagnosed diabetes.
3.1. Fasting insulin, C-peptide, and cognitive performance
Table 2 shows the variance in cognitive performance explained by
fasting insulin and C-peptide concentrations above and beyond that
explained by other factors (i.e. demographics, glycemic control,
cardiovascular risk factors, and depression). Demographic factors
alone (Model 1) explained one-fifth to one-fourth of the variance in
cognitive performance, with varying contributions across domains(i.e. memory function (18.0%), information processing speed (26.5%),
executive function and attention (22.8%)). Fasting insulin or
C-peptide was not associated with cognitive performance when
added to this first model, nor did they increase the total explained
variance of the model. Similar results were obtained when they were
added to subsequent models with glycemic control (Model 2) and
with cardiovascular risk factors and the presence of a depression
(Model 3). Specifically, across all models, the maximum increase in
explained variance by either fasting insulin or C-peptide was 0.1%
(p-value for F-tests ≥0.48). We did also not observe any quadratic
association of insulin or C-peptide with cognitive performance
(Table A2, Supplementary Material).
Of note, incorporating measures of glycemic control did not
explain more variance in cognitive performance than did demo-
graphics alone, whereas the inclusion of cardiovascular risk factors
and depression increased the explained variance with 1.1% to 2.4%.
This increase only reached statistical significance for information
processing speed (p-value for F-tests b0.01).3.2. HOMA2-IR and cognitive performance
Table 3 shows the variance in cognitive performance explained by
HOMA2-IR as a marker of insulin resistance in non-insulin treated
individuals (n = 641). Results for HOMA2-IR were roughly similar to
those for insulin and C-peptide in that HOMA2-IR was not associated
with cognitive performance and did not lead to an increase in the
explained variance in cognition.
Table 2
Variance in cognitive performance among individuals with type 2 diabetes explained by fasting plasma insulin and C-peptide concentrations (n = 806).
Memory function Information processing speed Executive function & attention
β (95% CI) R2 F-test β (95% CI) R2 F-test β (95% CI) R2 F-test
Model 1: 18.0% 26.5% 22.8%
+ (ln) Fasting insulin −0.013 (−0.076; 0.050) 18.0% (ΔR2 = 0.0%) 0.69 0.002 (−0.058; 0.062) 26.5% (ΔR2 = 0.0%) 0.94 0.018 (−0.044; 0.079) 22.8% (ΔR2 = 0.0%) 0.57
+ C-peptide −0.006 (−0.069; 0.057) 18.0% (ΔR2 = 0.0%) 0.85 −0.001 (−0.061; 0.059) 26.5% (ΔR2 = 0.1%) 0.97 0.004 (−0.058; 0.065) 22.8% (ΔR2 = 0.0%) 0.91
Model 2: 18.0% 0.84 26.9% 0.13 22.8% 0.68
+ (ln) Fasting insulin −0.011 (−0.075; 0.054) 18.0% (ΔR2 = 0.0%) 0.75 0.003 (−0.058; 0.063) 26.9% (ΔR2 = 0.0%) 0.93 0.014 (−0.048; 0.077) 22.9% (ΔR2 = 0.0%) 0.65
+ C-peptide −0.004 (−0.068; 0.061) 18.0% (ΔR2 = 0.0%) 0.92 −0.005 (−0.066; 0.056) 26.9% (ΔR2 = 0.0%) 0.87 b0.001 (−0.063; 0.062) 22.8% (ΔR2 = 0.0%) 1
Model 3: 19.5% 0.11 29.3% b0.01 24.1% 0.14
+ (ln) Fasting insulin −0.027 (−0.100; 0.047) 19.5% (ΔR2 = 0.1%) 0.48 −0.004 (−0.073; 0.065) 29.3% (ΔR2 = 0.0%) 0.91 0.014 (−0.058; 0.085) 24.1% (ΔR2 = 0.0%) 0.70
+ C-peptide −0.021 (−0.096; 0.053) 19.5% (ΔR2 = 0.0%) 0.58 −0.013 (−0.083; 0.057) 29.3% (ΔR2 = 0.0%) 0.72 −0.003 (−0.076; 0.069) 24.1% (ΔR2 = 0.0%) 0.93
Data are presented as standardized regression coefficient β (95% confidence interval), explained variance of the regression model R2, amount of variance explained by fasting insulin or C-peptide concentrations above and beyond other
variables in the regression model ΔR2, and p-value for F change F-test. Fasting insulin and C-peptide concentrations were each added to the following three basic regression models: (Model 1) age, sex, and educational level; (Model 2)
additional adjustment for HbA1c, and fasting glucose; (Model 3) additional adjustment for waist circumference, total/HDL-cholesterol ratio, use of lipid-modifying medication, systolic and diastolic blood pressure, use of antihypertensive
medication, smoking behavior (never/former/current), and the presence of a depression. Regression coefficients indicate the change in SD of cognitive domain scores per SD increase in fasting insulin or C-peptide concentrations. Fasting
insulin concentrations were transformed with the natural logarithm prior to analyses.
Table 3
Variance in cognitive performance among individuals with type 2 diabetes explained by HOMA2-IR (n = 641).
Memory function Information processing speed Executive function & attention
β (95% CI) R2 F-test β (95% CI) R2 F-test β (95% CI) R2 F-test
Model 1: 16.0% 25.6% 20.4%
+ (ln) HOMA2-IR 0.020 (−0.052; 0.092) 16.0% (ΔR2 = 0.0%) 0.59 0.049 (−0.019; 0.117) 25.8% (ΔR2 = 0.2%) 0.15 0.040 (−0.030; 0.110) 20.6% (ΔR2 = 0.2%) 0.26
Model 2: 16.0% 0.98 25.6% 0.84 20.5% 0.78
+ (ln) HOMA2-IR 0.020 (−0.052; 0.093) 16.0% (ΔR2 = 0.0%) 0.58 0.051 (−0.017; 0.119) 25.8% (ΔR2 = 0.3%) 0.14 0.039 (−0.031; 0.110) 20.6% (ΔR2 = 0.2%) 0.27
Model 3: 17.1% 0.44 27.8% 0.02 21.9% 0.25
+ (ln) HOMA2-IR 0.009 (−0.077; 0.095) 17.1% (ΔR2 = 0.0%) 0.84 0.056 (−0.024; 0.136) 28.0% (ΔR2 = 0.2%) 0.17 0.045 (−0.038;0.128) 22.0% (ΔR2 = 0.1%) 0.29
Data are presented as standardized regression coefficient β (95% confidence interval), explained variance of the regression model R2, amount of variance explained by HOMA2-IR above and beyond other variables in the regression model ΔR2,
and p-value for F change F-test. HOMA2-IR was added to the following three basic regression models: (Model 1) age, sex, and educational level; (Model 2) additional adjustment for HbA1c; (Model 3) additional adjustment for waist
circumference, total/HDL-cholesterol ratio, use of lipid-modifying medication, systolic and diastolic blood pressure, use of antihypertensive medication, smoking behavior (never/former/current), and the presence of a depression. Regression
coefficients indicate the change in SD of cognitive domain scores per SD increase in HOMA2-IR. HOMA2-IR was transformed with the natural logarithm prior to analyses.
827
S.L.C.G
eijselaers
et
al./
Journal
of
D
iabetes
and
Its
Com
plications
31
(2017)
824–830
828 S.L.C. Geijselaers et al. / Journal of Diabetes and Its Complications 31 (2017) 824–8303.3. Interaction analyses
Interaction analyses showed that age and sex did not clearly
modify the null-association of insulin-related variables with cognitive
performance (Table A3, Supplementary Material). Likewise, results
were similar between individuals with previously and newly diagnosed
diabetes (data not shown).
3.4. Sensitivity analyses
Because the use of exogenous insulin may affect the association
of insulin concentrations with cognitive performance, we reran
the analysis in the subgroup of individuals not treated with insulin
(n = 641). In this subgroup, the association between fasting insulin
and cognitive performance was also non-significant (Table A4,
Supplementary Material). Additional exclusion of individuals
receiving glucose-lowering medication with insulin secretion
stimulating effects (n excluded = 201) did not impact our findings
(data not shown). Likewise, after exclusion of individuals with
extreme values of fasting insulin (n = 6), C-peptide (n = 9), or
HOMA2-IR (n = 1), the results remained virtually unchanged (data
not shown). Alternative adjustment for 24-h blood pressure and
additional adjustment for diabetes duration or a history of CVD did
also not materially alter our results (data not shown).
4. Discussion
The present study shows that neither HOMA2-IR nor fasting
plasma insulin or C-peptide concentrations are associated with
cognitive performance among individuals in late middle age with
adequately controlled type 2 diabetes.
To our knowledge, this is the largest and most comprehensive
study to date examining the association between insulin-related
variables and cognitive performance among people with type 2
diabetes. Our results reinforce those of previous smaller studies
showing that insulin-related variables are unrelated to cognitive
performance15–19 and cognitive decline18,20 among individuals with
diabetes, even in those with less well-controlled diabetes.17 A few
other small studies,21–28 some of which evaluated overlapping
populations,23–25 have reported seemingly contradictory results, but
these studies were often conducted in selected populations, for
example focusing on individuals with mild cognitive impairment,21,22
and did not always adequately control for demographic factors.21,22,26,27
Collectively, the currently available data thus strongly suggest that, in a
population-based sample of individuals with type 2 diabetes, measures
of peripheral insulin resistance are unrelated to cognitive performance.
The lack of an association between peripheral insulin resistance
and cognitive performance in type 2 diabetes might be somewhat
surprising given that such an association has been established in
(middle-aged) individuals without diabetes (e.g.4–6). The association
of insulin resistance with cognitive performance might thus differ by
diabetes status, which is supported by two previous studies showing
that fasting hyperinsulinemia29 and higher HOMAvalues19 are associated
withworse cognitive performance19 and an increased risk for dementia29
among individuals without diabetes, but not in those with diabetes. One
potential explanation for this discrepancy lies in the receptor-mediated
transport of insulin across the blood–brain barrier,which has been shown
to decrease with the degree of insulin resistance.30 As a consequence,
peripheral insulin may not accurately reflect central (i.e. cerebral)
concentrations of insulin in those with diabetes. In addition, it has been
suggested that peripheral and cerebral insulin resistance does not
necessarily co-exist.31 Alternatively, however, the discrepancy between
our findings and those of previous studies in people without diabetes
could also relate to the potential inaccuracy of fasting insulin and
HOMA2-IR as measures of (peripheral) insulin resistance in diabetes, not
only because β-cells often lose their insulin secretion capacity as thediseaseprogresses, but alsobecauseoral glucose-loweringmedication can
enhance insulin secretion.32 Note, however, that similar null results were
observed when additional adjustments were made for diabetes duration
or when analyses were restricted to those individuals not using
glucose-lowering medication with insulin secretion stimulating effects.
In a broader context, it is possible that the factors that contribute to
cognitive dysfunction among individuals with type 2 diabetes differ
from those in the general population. Noteworthy in this regard is our
observation that traditional cardiovascular risk factors explained only
a marginal amount of variance (i.e. 1.1% to 2.4%) in cognitive
performance beyond that explained by demographics, even when
we used the 24-h blood pressure data. Although cardiovascular risk
factors, such as obesity, hypertension, and dyslipidemia, may be
associated with an increased risk of cognitive dysfunction in the
general population,33,34 a recent review concluded that it remains to
be determined whether these factors are also linked to cognitive
performance among individuals with type 2 diabetes.35 It is
conceivable that the earlier detection and more intensive treatment
of cardiovascular risk factors in individuals diagnosed with diabetes
might limit the potential detrimental effects these factors can have on
the brain. Likewise, it is possible that multiple cardiovascular risk
factors do not necessarily exert additive effects on the brain. On the
contrary, however, the ubiquity of cardiovascular co-morbidities in
people with type 2 diabetes could limit the ability to detect
associations between cardiovascular risk factors and cognitive
performance in these individuals. In addition, previous studies have
suggested that cardiovascular risk factors in midlife are more closely
associated with late-life than with midlife cognitive performance36
and that cardiovascular risk factors, particularly blood pressure, might
be non-linearly rather than linearly related to cognitive performance
among individuals with type 2 diabetes.37 Hence, the relatively small
proportion of variance explained by traditional cardiovascular risk
factors in the present study does not undoubtedly mean that these
factors are irrelevant to cognitive performance in diabetes.
Although we can conclude from our data that measures of
peripheral insulin resistance are unrelated to cognitive performance
in type 2 diabetes, we cannot preclude the possibility that central
insulin resistance may affect cognitive performance. As mentioned
above, this is not only because peripheral insulin concentrations may
not adequately reflect cerebral concentrations, but also because of the
possibility of peripheral insulin resistance being not invariably
accompanied by central insulin resistance.31 Two recent pilot studies
in a small sample of older individuals with type 2 diabetes and
age-matched healthy individuals have demonstrated that a single
dose of intranasal insulin can acutely improve visuospatial memory
performance,38,39 highlighting the effects cerebral insulin may have
on the brain in diabetes. Experimental studies have identified
multiple pathways through which insulin signaling may affect
cognitive performance. It, for example, affects synaptic plasticity,
modulates neurotransmitter release, and contributes to the glucose
availability in the brain.7 At the same time, insulin is known to interact
with the metabolism of amyloid-β and tau,7 key proteins in the
pathogenesis of Alzheimer's disease. Unfortunately, however, it is
currently not possible tomeasure insulin signaling in the human brain
in vivo. Consequently, the role of central insulin signaling in cognitive
performance remains elusive.
Strengths of the present study include its relatively large sample
size and the use of a comprehensive neuropsychological test battery
to assess cognitive performance acrossmultiple domains. The findings
discussed above should, however, also be viewed in the light of a few
limitations. Most importantly, our study populationwas characterized
by a relatively large proportion of highly-educated (29%) individuals,
a relatively young age (mean age 62 ± 8 years), and overall adequate
glycemic control (mean HbA1c 6.9 ± 1.1% (52 ± 12 mmol/mol)).
This seemed partly enhanced by our complete case analysis approach
(e.g. for educational level and age, Table A1 (Supplementary
829S.L.C. Geijselaers et al. / Journal of Diabetes and Its Complications 31 (2017) 824–830Material)), and may not only have resulted in slightly underestimated
effects, but also somewhat limits the generalizability of our findings.
Another limitation might be that the venous blood sampling and
cognitive assessment were not performed at the same day. Conse-
quently, wemay havemissed acute effects of hyperinsulinemia due to
intraindividual day-to-day variability in insulin resistance.40 In
addition, we were unable to fully account for the biphasic nature
of fasting insulin concentrations during the pathogenesis of
diabetes, where the early phase of diabetes is characterized by
hyperinsulinemia and β-cells become progressively exhausted as the
diseases progresses. We believe, however, that these limitations
are unlikely to fully explain the null-associations observed in the
present study.5. Conclusions
The present study shows that peripheral hyperinsulinemia and
insulin resistance are unrelated to cognitive performance among
individuals with type 2 diabetes. From an etiological perspective, our
findings suggest that peripheral insulin resistance is not involved in
cognitive performance among these people, thereby challenging the
concept that insulin has cerebral effects, although peripheral and
cerebral insulin resistance may not necessarily coincide. From a
clinical perspective, our results indicate that measures of peripheral
insulin resistance are unlikely to explain the variety of cognitive
problems among individuals with diabetes and hence are unlikely to
be useful markers to screen individuals with diabetes for cognitive
problems or to identify thosewho are likely to develop such problems.
The present study also highlights that the factors that are associated
with cognitive performance may differ by diabetes status. This implies
that individuals with and without diabetes might benefit from a
different approach for the prevention and treatment of cognitive
problems. Further studies are warranted to elucidate the effects of
central insulin resistance on cognition in diabetes and to adequately
address the possibility of central and peripheral insulin resistance
being differentially associated with cognitive performance.Acknowledgments
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